PHARMA KING
DILIP SHANGHVI 62 Industrialist
Because, as managing director of Sun Pharmaceuticals, the world’s fourth largest pharma company, he is driving a restructuring process post the acquisition of troubled Ranbaxy in March 2015 that will see pruning plants and staff, re-examining trade and incentive policies, and streamlining quality control processes
Because, despite a Rs 46,800 crore erosion in his net worth after his company’s stocks plunged on FDA warnings at his biggest factories and price slippage in the US market, he is the sixth richest in India and the country’s richest in healthcare
Because he has the prime minister’s ear and on February 1 this year, was nominated director to the Central Board of the Reserve Bank of India until
March 10, 2021
VALUE CREATOR Started pharma trading firm with Rs 10,000 borrowed from his father in 1982. Sun Pharma had a market capitalisation of Rs 1.23 lakh crore as on April 17
MOST EMBARRASSING MOMENT When Sun Pharma reported its first loss in 12 years in August 2017 amid regulatory headaches and a weakening market for generic drugs
BUSINESS MANTRA “A good entrepreneur is able to spot an opportunity before others see it. He is able to risk money for opportunities that don’t exist today”